Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322140 | 0.91 | GRIN1 (0.40) | GRIN1GRIN2BKDM1AKCNH2KDM4E | |
| SCHEMBL6742821 | 0.89 | KDM4E (0.51) | GRIN1GRIN2BKCNH2KDM4EALDH1A1 | |
| SCHEMBL6733487 | 0.88 | CHRNA7 (0.40) | GRIN1GRIN2BKDM1AKCNH2MMP2 | |
| SCHEMBL6738989 | 0.87 | DPP4 (0.41) | GRIN1GRIN2BKDM1AKCNH2KDM4E | |
| SCHEMBL6614408 | 0.86 | GPR119 (0.46) | GRIN1GRIN2BKDM1AKCNH2 | |
| SCHEMBL6738018 | 0.85 | KCNH2 (0.39) | GRIN1GRIN2BKDM1AKCNH2KDM4E | |
| SCHEMBL6995039 | 0.83 | GRIN1 (0.42) | GRIN1GRIN2BKDM1AKCNH2KDM4E | |
| SCHEMBL6997502 | 0.83 | KCNH2 (0.46) | GRIN1GRIN2BKCNH2KDM4EALDH1A1 | |
| SCHEMBL6997487 | 0.81 | KDM4E (0.49) | GRIN1GRIN2BKCNH2KDM4EALDH1A1 | |
| SCHEMBL6614804 | 0.80 | KCNH2 (0.37) | GRIN1GRIN2BKDM1AKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | GRIN1 849/4885GRIN2B 549/4885KDM1A 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.